Latest News

Can ‘new science’ cure biopharma’s ‘compressive disruption’ problem?

genetic testing, reimbursement

A new report by Accenture suggests that over the next three years, 54 percent of biopharma industry revenues could come from new advancements in medical science and technology – and combinations of the two.

Source link

Related posts

A Universal Marginalizer for Amortized Inference in Generative Models


Medical News Today: Screen time disrupts sleep by resetting internal clocks


Study reveals how stress can curb the desire to eat in an animal model


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy